Haemonetics (HAE) Tops Q4 EPS by 2c, provides guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $102.84 -0.08%
Revenue Growth %: +5.5%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.5%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $1.24, $0.02 better than the analyst estimate of $1.22. Revenue for the quarter came in at $331 million versus the consensus estimate of $330.66 million.
GUIDANCE:
Haemonetics sees FY2026 EPS of $4.70-$5.00, versus the consensus of $4.54.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- U.S. Bancorp (USB) Raises Quarterly Dividend 3.8% to $0.54; 3.5% Yield
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
